Is there still a role for bilateral orchidectomy in androgen-deprivation therapy for metastatic prostate cancer?

References

• Huggins C, Stevens RE Jr, Hodges CV. Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209–223.
   Google Scholar
• Desmond AD, Arnold AJ, Hastie KJ. Subcapsular orchiectomy under local anaesthesia. Technique, results and implications. Br J Urol. 1988;61:143–145.
   Google Scholar
• Oefelein MG, Feng A, Scolieri MJ, et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000;56:1021–1024.
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Briers E, et al. Guidelines on prostate cancer: cost-effectiveness of hormonal therapy options. European Association of Urology Guidelines; 2015. [cited 2019 November]. Available from: https://uroweb.org/wp-content/uploads/EAU-Extended-Guidelines-2015-Edn.pdf
   Google Scholar
• Heber D, Dodson R, Stoskopf C, et al. Pituitary desensitisation and the regulation of pituitary gonadotropin-releasing hormone (GnRH) receptors following chronic administration of a superactive GnRH analog and testosterone. Life Sci. 1982;30:2301–2308.
   Web of Science ®Google Scholar
• McKillop C. Interview with Professor Ulf Tunn: lHRHa: what’s new? Interview by Christine McKillop. Eur Urol. 2007;51:275–277.
   Web of Science ®Google Scholar
• Tomera K, Gleason D, Gittelman M, et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol. 2001;165:1585–1589.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68–80.
   PubMed Web of Science ®Google Scholar
• Broqua P, Riviere PJ, Conn PM, et al. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther. 2002;301:95–102.
   PubMed Web of Science ®Google Scholar
• Van Poppel H, Tombal B, de la Rosette JJ, et al. Degarelix: a novel gonadotrophin-releasing hormone (GnRH‎)‎ receptor blocker – results from a 1-yr, multicentre, randomised, phase 2 dose-finding study in the treatment of prostate cancer. Eur Urol. 2008;54:805–815.
   PubMed Web of Science ®Google Scholar
• Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531–1538.
   PubMed Web of Science ®Google Scholar
• Higano C. Androgen deprivation therapy: monitoring and managing the complications. Hematol Oncol Clin North Am. 2006;20:909–923.
   PubMed Web of Science ®Google Scholar
• Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–1261.
   PubMed Web of Science ®Google Scholar
• Lu-Yao G, Stukel TA, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol. 2004;171:2285–2290.
   PubMed Web of Science ®Google Scholar
• Newschaffer CJ, Otani K, McDonald MK, et al. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst. 2000;92:613–621.
   PubMed Web of Science ®Google Scholar
• Awad MA, Denic S, El Taji H. Validation of the European organization for research and treatment of cancer quality of life questionnaires for Arabic-speaking populations. Ann NY Acad Sci. 2008;1138:146–154.
   Web of Science ®Google Scholar
• Huijer HA, Sagherian K, Tamim H. Validation of the Arabic version of the EORTC QLQ-C30 quality of life questionnaire among cancer patients in Lebanon. Qual Life Res. 2013;22:1473–1481.
   PubMed Web of Science ®Google Scholar
• Fayers P, Aaronson NK, Bjordal K, et al. EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: EORTC Quality of Life Group; 2001; p. 86.
   Google Scholar
• Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A contemporary prostate cancer grading system: A validated alternative to the Gleason score. Eur Urol. 2016;69:428–435.
   PubMed Web of Science ®Google Scholar
• Perachino M, Cavalli V, Monferrato C. Testosterone (T‎)‎ level correlates with survival in pts with advanced prostate cancer (APC): the lower is really the better. J Urol. 2008;179:179–180.
   Web of Science ®Google Scholar
• Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol. 2007;178:1290–1295.
   PubMed Web of Science ®Google Scholar
• Klotz L, Miller K, Crawford ED, et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol. 2014;66:1101–1108.
   PubMed Web of Science ®Google Scholar
• Sun M, Choueiri T, Hamnvik O, et al. Comparison of gonadotropin-releasing hormone agonists and orchiectomy. JAMA Oncol. 2016;4:500–507.
   Google Scholar
• Van Asseldonk B, Black P, Elterman DS. Chemical vs surgical ADT in metastatic prostate cancer: a comparison of side effects. Commentary on comparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen deprivation therapy. Urology. 2016;93:3–4.
   PubMed Web of Science ®Google Scholar